In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Taro

This article was originally published in The Tan Sheet

Executive Summary

Taro: First Phase III trials of the generic drug company's prescription one-day treatment for vaginal yeast infections are complete. Taro plans to file an NDA in 1998 and is seeking a multinational partner for co-marketing of store brand and branded product. Taro is also talking to companies interested in its "NonSpil" technology for drug delivery; the pourable substance will remain in a spoon that has been turned upside down. The initial patent application was filed in April 1993...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel